根据 位华尔街分析师的预测,ACRO Biomedical Co Ltd 的收入预期范围从 $ 到 $
ACRO Biomedical Co Ltd 的盈利质量评分是多少?
ACRO Biomedical Co Ltd 的盈利质量评分为 A-/59.598984。该评分基于盈利能力、增长、现金生成与资本分配以及杠杆四个维度。
ACRO Biomedical Co Ltd 何时发布财报?
ACRO Biomedical Co Ltd 的下一份财报预计在 2026-05-12 发布
ACRO Biomedical Co Ltd 的预期收益是多少?
根据华尔街分析师的预测,ACRO Biomedical Co Ltd 的预期收益为 $
ACRO Biomedical Co Ltd 是否超出收益预期?
ACRO Biomedical Co Ltd 最近的收益为 $, 预期。
关键数据
前收盘价
$0.026
开盘价
$0.026
当日区间
$0.026 - $0.026
52周范围
$0.0007 - $0.1
交易量
66
平均成交量
56
股息收益率
--
每股收益(TTM)
-0.00
市值
$1.5M
什么是 ACBM?
Acro Biomedical Co. Ltd. engages in the business of developing and marketing nutritional products that promote wellness and a healthy lifestyle. The company is headquartered in Fishers, Indiana. The company went IPO on 2016-06-23. The firm is focused on developing and marketing nutritional products that promote wellness and a healthy lifestyle. The firm's business consists of selling cordyceps related products that is used in traditional Chinese medicine. Cordyceps is a fungus which is a combination of a caterpillar and a fungus, which is found at altitudes above 4500 meters (m) in Sikkim. The firm is engaged in the purchase of products from three suppliers in Taiwan and the sale of these products to four unrelated customers. The company sells products in bulk to companies who may use the Company's products as ingredients in their products or sell the products they purchase from the Company to their own customers.